Absci
AI-driven drug creation
- B2B
- AI-native
About Absci
Generative AI drug creation company combining AI and wet lab technologies to accelerate biologics development, optimizing multiple drug characteristics for therapeutic benefit
Key facts
- Industry
- Biotechnology Research
- Company size
- 51–250 employees
- Headquarters
- Vancouver, Washington, United States
- Founded
- 2011
- Revenue
- $2.8MFY2025, publicly reported
- Website
- absci.com
- linkedin.com/company/absci
Absci in the news
- Absci Corporation (NASDAQ:ABSI) Stock Has Average Target Price of $13.71
Absci Corporation receives a "Moderate Buy" consensus from analysts with an average target price of $13.71, despite missing quarterly earnings and revenue estimates.
- Phase 2 Trial Plans Could Be A Game Changer For Absci Stock (ABSI)
Absci unveiled its Phase 2 STORYLINE trial design for ABS-201 in endometriosis, linking its AI drug creation platform to a mid-stage clinical asset, despite current financial losses and concentration risks.
- Weekly Recap: ABS-201 Phase 2 STORYLINE and Needham $11 Buy
Absci is progressing ABS-201 to a global Phase 2 trial for endometriosis, with an anticipated mid-2027 start, while Needham maintains an $11 price target.
- Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027
Absci plans to start a mid-stage clinical trial for its endometriosis drug candidate, ABS-201, in mid-2027.
- Absci (NASDAQ:ABSI) Stock Jumps 6.1% - Still a Buy?
Absci's stock price increased by 6.1% on Tuesday, with a "Moderate Buy" analyst consensus despite missing recent earnings and revenue estimates, while institutional ownership stands at 52.05%.
Absci at a glance
Absci is a B2B company in the Biotechnology Research industry, headquartered in Vancouver, Washington, United States.
Absci was founded in 2011.
Absci has 51–250 employees.
Absci's revenue is $2.8M (FY2025, publicly reported).
Selling to companies like Absci?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies